Newron Pharmaceuticals S.p.A. (NP5.DE)
EUR 8.8
(-0.34%)
EUR 8.8
(-0.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.22 Million EUR | 3.04% |
| 2022 | -17.49 Million EUR | -17.39% |
| 2021 | -14.9 Million EUR | 29.04% |
| 2020 | -20.99 Million EUR | -3.91% |
| 2019 | -20.2 Million EUR | -34.4% |
| 2018 | -15.03 Million EUR | -184.65% |
| 2017 | -5.28 Million EUR | 65.33% |
| 2016 | -15.23 Million EUR | 33.22% |
| 2015 | -22.81 Million EUR | -126.01% |
| 2014 | -10.09 Million EUR | -42.22% |
| 2013 | -7.09 Million EUR | -198.86% |
| 2012 | -2.37 Million EUR | 63.15% |
| 2011 | -6.44 Million EUR | 68.63% |
| 2010 | -20.54 Million EUR | 12.5% |
| 2009 | -23.48 Million EUR | -43.49% |
| 2008 | -16.36 Million EUR | -47.57% |
| 2007 | -11.08 Million EUR | 32.39% |
| 2006 | -16.4 Million EUR | -9.93% |
| 2005 | -14.91 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -9.55 Million EUR | 0.0% |
| 2023 Q2 | -7.01 Million EUR | 0.0% |
| 2023 Q4 | -9.27 Million EUR | 0.0% |
| 2023 FY | -16.96 Million EUR | 3.04% |
| 2022 Q4 | -8.75 Million EUR | 0.0% |
| 2022 Q2 | -8.89 Million EUR | 0.0% |
| 2022 FY | -17.49 Million EUR | -17.39% |
| 2021 Q4 | -6.01 Million EUR | 0.0% |
| 2021 FY | -14.9 Million EUR | 29.04% |
| 2021 Q2 | -9.04 Million EUR | 0.0% |
| 2020 FY | -20.99 Million EUR | -3.91% |
| 2020 Q4 | -10.44 Million EUR | 0.0% |
| 2020 Q2 | -10.5 Million EUR | 0.0% |
| 2019 Q2 | -14.28 Million EUR | -182.8% |
| 2019 Q1 | -5.05 Million EUR | 32.23% |
| 2019 FY | -20.2 Million EUR | -34.4% |
| 2019 Q4 | -6.21 Million EUR | 0.0% |
| 2018 Q1 | -3.75 Million EUR | 45.05% |
| 2018 FY | -15.03 Million EUR | -184.65% |
| 2018 Q4 | -7.45 Million EUR | 0.0% |
| 2018 Q2 | -7.58 Million EUR | -101.69% |
| 2017 Q1 | -1.32 Million EUR | 79.63% |
| 2017 FY | -5.28 Million EUR | 65.33% |
| 2017 Q4 | -6.84 Million EUR | 0.0% |
| 2017 Q2 | 1.55 Million EUR | 217.99% |
| 2016 Q1 | -3.8 Million EUR | 76.03% |
| 2016 Q2 | -8.75 Million EUR | -129.81% |
| 2016 FY | -15.23 Million EUR | 33.22% |
| 2016 Q4 | -6.48 Million EUR | 0.0% |
| 2015 Q1 | -5.7 Million EUR | -3.73% |
| 2015 Q2 | -6.92 Million EUR | -21.37% |
| 2015 Q4 | -15.89 Million EUR | -178.63% |
| 2015 Q3 | -5.7 Million EUR | 17.61% |
| 2015 FY | -22.81 Million EUR | -126.01% |
| 2014 Q4 | -5.49 Million EUR | -117.89% |
| 2014 FY | -10.09 Million EUR | -42.22% |
| 2014 Q2 | -4.59 Million EUR | -82.11% |
| 2014 Q1 | -2.52 Million EUR | 45.75% |
| 2014 Q3 | -2.52 Million EUR | 45.09% |
| 2013 Q3 | -1.77 Million EUR | 27.45% |
| 2013 Q4 | -4.65 Million EUR | -162.16% |
| 2013 Q2 | -2.44 Million EUR | -37.84% |
| 2013 FY | -7.09 Million EUR | -198.86% |
| 2013 Q1 | -1.77 Million EUR | 0.0% |
| 2012 Q1 | -593.75 Thousand EUR | 0.0% |
| 2012 FY | -2.37 Million EUR | 63.15% |
| 2012 Q4 | -1.77 Million EUR | -198.86% |
| 2012 Q3 | -593.75 Thousand EUR | 0.0% |
| 2012 Q2 | -593.75 Thousand EUR | 0.0% |
| 2011 Q2 | -1.61 Million EUR | 0.0% |
| 2011 Q4 | -593.75 Thousand EUR | 63.15% |
| 2011 FY | -6.44 Million EUR | 68.63% |
| 2011 Q1 | -1.61 Million EUR | 0.0% |
| 2011 Q3 | -1.61 Million EUR | 0.0% |
| 2010 Q3 | -5.13 Million EUR | 0.0% |
| 2010 Q4 | -1.61 Million EUR | 68.63% |
| 2010 FY | -20.54 Million EUR | 12.5% |
| 2010 Q1 | -5.13 Million EUR | 0.0% |
| 2010 Q2 | -5.13 Million EUR | 0.0% |
| 2009 Q4 | -5.13 Million EUR | 12.5% |
| 2009 FY | -23.48 Million EUR | -43.49% |
| 2009 Q3 | -5.87 Million EUR | 0.0% |
| 2009 Q2 | -5.87 Million EUR | 0.0% |
| 2009 Q1 | -5.87 Million EUR | 0.0% |
| 2008 Q1 | -4.09 Million EUR | 0.0% |
| 2008 Q4 | -5.87 Million EUR | -43.49% |
| 2008 FY | -16.36 Million EUR | -47.57% |
| 2008 Q2 | -4.09 Million EUR | 0.0% |
| 2008 Q3 | -4.09 Million EUR | 0.0% |
| 2007 FY | -11.08 Million EUR | 32.39% |
| 2007 Q4 | -4.09 Million EUR | -47.57% |
| 2007 Q3 | -2.77 Million EUR | 0.0% |
| 2007 Q2 | -2.77 Million EUR | 0.0% |
| 2007 Q1 | -2.77 Million EUR | 0.0% |
| 2006 Q2 | -4.01 Million EUR | 0.0% |
| 2006 FY | -16.4 Million EUR | -9.93% |
| 2006 Q3 | -4.01 Million EUR | 0.0% |
| 2006 Q1 | -4.01 Million EUR | 0.0% |
| 2006 Q4 | -2.77 Million EUR | 30.91% |
| 2005 FY | -14.91 Million EUR | 0.0% |
| 2005 Q1 | -3.69 Million EUR | 0.0% |
| 2005 Q2 | -3.69 Million EUR | 0.0% |
| 2005 Q3 | -3.69 Million EUR | 0.0% |
| 2005 Q4 | -4.01 Million EUR | -8.73% |
| 2004 Q4 | -3.69 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Redcare Pharmacy NV | -12.04 Million EUR | -34.74% |